Amiselimod

N/A

Report date: 2024/01/03 11:41:36
NME

Base Information

Drug NameAmiselimod
Drug Alias NameAmiselimodum阿米莫德Amiselimod - Mitsubishi Tanabe Pharma CorporationAmiselimod Hydrochloride2240442 (free base) +[8] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionSphingosine 1-Phosphate Receptor 1 antagonists
TargetsSphingosine 1-Phosphate Receptor 1
Therapy Area/IndicationsPlaque psoriasisLupus Erythematosus, SystemicMultiple Sclerosis, Relapsing-Remitting +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumBulgaria +[31] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesMitsubishi Tanabe Pharma Corp
China Registration ClassN/A

Develop Information

Active CompaniesSalix PharmaceuticalsBiogen IncBausch Health Americas Inc
Inactive CompaniesMitsubishi Tanabe Pharma Corp
Active IndicationsColitis, Ulcerative
Inactive IndicationsPlaque psoriasisLupus Erythematosus, SystemicMultiple Sclerosis, Relapsing-Remitting +[5] 

Other Information

ATC CodeN/A
Related LinksN/A